Themis Medicare Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2025.
THEMISMED · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Themis Medicare reported a weak set of Q1 FY26 numbers, swinging to a standalone loss of ₹1,537.37 lakhs compared to a profit of ₹1,871.47 lakhs in the same quarter last year. Revenue from operations fell about 21% year-on-year to ₹9,757.77 lakhs, while total expenses rose roughly 14% to ₹11,267.82 lakhs, squeezing margins sharply. The company also booked an exceptional charge of ₹129.39 lakhs linked to the strike-off of its UK subsidiary, Carpo Medicals Limited. On the corporate side, the board appointed Ms. Neha Thakore as an additional woman independent director and Mr. Viraj Save as Executive President for Sales & Marketing, and fixed September 5, 2025 as the record date for the FY25 final dividend. The board also formally withdrew the proposed merger with Gujarat Themis Biosyn Limited after GTBL decided to remain independent.
The sharp swing to a quarterly loss and a 20%+ drop in revenue are negative for short-term sentiment, but the dividend record date offers some support for existing shareholders. The withdrawn merger removes a potential growth lever, so the stock may react negatively in the near term.